XML 129 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Compounds
shares
Dec. 31, 2022
USD ($)
shares
Mar. 31, 2023
USD ($)
Compounds
shares
Mar. 31, 2022
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]            
Cash and cash equivalents $ 5,295,000 $ 20,196,000 $ 5,295,000 $ 20,196,000 $ 15,301,000 $ 28,675,000
Restricted cash 143,000 143,000 143,000 143,000 143,000 143,000
Accumulated deficit $ (336,624,000)   (336,624,000)   (324,998,000) (307,739,000)
Cash flow from operations     $ 11,982,000 7,675,000 $ 12,408,000 $ 8,453,000
Issuance of common stock | shares 9,838,755   9,838,755   8,716,906 8,710,627
Restricted cash         $ 100,000 $ 100,000
Impairment of long-lived assets         0 0
Acquired in-process research and development accrued expenses $ 0   $ 0   2,000,000 0
Dilutive effect $ 0 $ 0 $ 0 $ 0 $ 0 $ 0
Common stock equivalents excluded from computing diluted net loss per share | shares     800,000 1,500,000 1,600,000 1,200,000
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]         us-gaap:UsefulLifeTermOfLeaseMember  
Maximum [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Maturity of highly liquid investment         3 months  
Useful life of fixed assets, range         7 years  
Minimum [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Useful life of fixed assets, range         1 year  
At-The-Market Facility [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Issuance of common stock | shares 934,621   934,621   0  
Metacrine's FXR Program [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Number of clinically tested compounds | Compounds     2      
Number of discovery or preclinical compounds | Compounds     2,000      
Metacrine, Inc. [Member] | Metacrine's FXR Program [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Number of clinically tested compounds | Compounds         2  
Number of discovery or preclinical compounds | Compounds         2,000  
Asset Acquisition, Price of Acquisition, Expected         $ 4,000,000  
Upfront payment paid         2,000,000  
Acquired in-process research and development accrued expenses         $ 2,000,000